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Abstract
Zebrafish have recently emerged as an attractive model for the in vivo bioassay-guided isolation and characterization
of pharmacologically active small molecules of natural origin. We carried out a zebrafish-based phenotypic screen of
over 3000 plant-derived secondary metabolite extracts with the goal of identifying novel small-molecule modulators of
the BMP and Wnt signaling pathways. One of the bioactive plant extracts identified in this screen – Jasminum
gilgianum, an Oleaceae species native to Papua New Guinea – induced ectopic tails during zebrafish embryonic
development. As ectopic tail formation occurs when BMP or non-canonical Wnt signaling is inhibited during the tail
protrusion process, we suspected a constituent of this extract to act as a modulator of these pathways. A bioassay-
guided isolation was carried out on the basis of this zebrafish phenotype, identifying para-coumaric acid methyl ester
(pCAME) as the active compound. We then performed an in-depth phenotypic analysis of pCAME-treated zebrafish
embryos, including a tissue-specific marker analysis of the secondary tails. We found pCAME to synergize with the
BMP-inhibitors dorsomorphin and LDN-193189 in inducing ectopic tails, and causing convergence-extension defects
in compound-treated embryos. These results indicate that pCAME may interfere with non-canonical Wnt signaling.
Inhibition of Jnk, a downstream target of Wnt/PCP signaling (via morpholino antisense knockdown and
pharmacological inhibition with the kinase inhibitor SP600125) phenocopied pCAME-treated embryos. However,
immunoblotting experiments revealed pCAME to not directly inhibit Jnk-mediated phosphorylation of c-Jun,
suggesting additional targets of SP600125, and/or other pathways, as possibly being involved in the ectopic tail
formation activity of pCAME. Further investigation of pCAME’s mechanism of action will help determine this
compound’s pharmacological utility.
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Introduction
Chemical genetics in zebrafish enables [1] the identification
of bioactive small molecules based on their ability to induce
specific developmental dysmorphologies or behaviors [2], the
association of in vivo phenotypes induced by these compounds
with the modulation of key signaling pathways, and [3]
ultimately, the elucidation of their biological targets. Because of
multiple genetic screens carried out to date, a wide range of
mutant phenotypes in zebrafish have been thoroughly
characterized and reported, including for genes and pathway
components of the BMP (Bone Morphogenetic Protein) and
Wnt (Wingless/Int) signaling pathways. Dorsoventral (DV) and
anterior-posterior (AP) axis defects as well as ectopic tail
formation have been reported in BMP/Wnt mutant or transgenic
zebrafish [4–7]. The recent identification of dorsomorphin, a
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novel small-molecule inhibitor of BMP signaling, proved the
usefulness of phenotype-based compound screening in
zebrafish embryos. This molecule induced severe dorsalization
(DV patterning defect) in developing embryos [8] and to date
this molecule and some of its derivatives have been
extensively studied as modifiers of iron homeostasis, bone
formation and metabolism [9]. Despite progress in the field,
target elucidation remains the major challenge in the field of
chemical genetics [10].
Over the last decade, zebrafish have proven increasingly
useful as an animal model in the early drug discovery process
[11,12]. For example, PGE2 was identified in a zebrafish
screen for small molecules capable of causing the proliferation
of hematopoietic stem cells (HSCs) in vivo [13], and is now in
clinical trials as part of a novel HSC transplantation protocol.
Using zebrafish for early-stage drug discovery has several key
advantages. Zebrafish are highly fecund, rapidly develop ex
utero and require simple husbandry. They are small, so only
sub-milligram amounts of compounds are needed for
screening. Their optical transparency permits live visualization
using standard light microscopy. All this features have made
this model very cost-efficient to use [11]. Furthermore,
established genetic tools such as antisense morpholino
oligonucleotides and targeted mutations via TALENs allow for
relatively rapid disease modeling [14,15].
We and others have recently established zebrafish as a
platform for natural product discovery [2,16] using bioassay-
guided fractionation of secondary metabolite extracts to identify
plant-derived small molecules with anti-angiogenic [17], anti-
epileptic [3], and anti-inflammatory [1] activity. Molecules that
can modulate BMP or Wnt signaling pathways are also of
pharmacological interest, as these conserved pathways are not
only crucial for embryonic development, but are also important
in adult homeostasis. Aberrant signaling is linked with several
major diseases such as cancer, osteopathies and Alzheimer’s
disease. New drug-like lead compounds that target and
modulate BMP or Wnt signaling could therefore be of
therapeutic utility [18–20].
We carried out a zebrafish-based phenotypic screen for BMP
and Wnt signaling modulators using the Strathclyde Natural
Products Library as a potential source of novel, bioactive
compounds. The library consists of 5000 methanolic plant
extracts representing 90% of plant families worldwide. Several
active extracts were in this zebrafish screen that mimicked
phenotypes previously reported in zebrafish mutants for BMP
or Wnt signaling pathway members. Of particular interest was
an extract of Jasminum gilgianum (Oleaceae), a plant native to
Papua New Guinea. As the embryos treated with crude extract
displayed ectopic tails, we postulated that a constituent of this
plant extract may act as a modulator of BMP and/or non-
canonical Wnt signaling [6,7].
The aim of this study was to isolate the active constituent of
Jasminum gilgianum responsible for inducing ectopic tail
formation and to characterize the compound’s putative
modulatory activity on BMP and/or non-canonical Wnt
signaling. Our results showed that para-coumaric acid methyl
ester is responsible for the bioactivity of Jasminum gilgianum




Dimethyl sulfoxide (DMSO, 99.9% spectroscopy grade),
chloroform and methanol (HPLC grade) were purchased from
Acros Organics. Ethylacetate was purchased from ChemLab.
Para-coumaric acid methyl ester (pCAME) was purchased from
Frinton Laboratories (New Jersey, USA).
Plant Material
The Strathclyde Natural Products Library (SNPL) was
available for this study through collaboration with the
Strathclyde Institute for Drug Research (SIDR) at the University
of Glasgow and the Scottish Universities Life Science Alliance
(SULSA). The SNPL is composed of 5000 methanolic plant
extracts, representing 90% of plant families, pre-treated to
remove the reactive compounds commonly responsible for
false positive results in screening assays (e.g. tannins). The
samples, available in 96-well plates, were dissolved in 100%
DMSO at a concentration of 10 mg/ml and were kept at -20°C.
Prior to use, the plates were thawed and centrifuged at room
temperature, and each well was mixed thoroughly by pipetting
before an aliquot was taken for screening. Aliquots of
methanol-extracted Jasminum gilgianum leaves were dissolved
in 100% DMSO for zebrafish experiments or in 100% methanol
for chromatographic fractionation.
Bioassay-Guided Fractionation and Isolation Of Active
Constituent
Dry methanolic extract of Jasminum gilgianum was
separated by thin layer chromatography (TLC) on 0.2 mm
Alugram SIL G/UV254 plates (Macherey-Nagel). Ten
milligrams of the extract were dissolved in 100 µL methanol
and loaded manually onto a TLC plate. Separation was
performed in a saturated chamber using chloroform/
ethylacetate (80/20). After TLC development, constituents
separated as bands were revealed under UV irradiation at 254
and 365 nm, and by spraying the plate with a universal reagent
(1% vanillin/H2SO4). Individual bands of non-sprayed plates
were extracted with methanol, evaporated to dryness, and
redissolved in DMSO for bioactivity testing (see further).
In order to obtain a larger amount of the active band,
preparative column chromatography of 0.2 g methanolic extract
of J. gilgianum was performed using silica gel (60 mesh, 15 to
40 nm, Merck) with chloroform/ethylacetate (80/20). Fractions
of about 2 mL were collected, and the fractions known to
contain the active band (as monitored by TLC) were pooled.
Several preparative runs yielded 14.4 mg of the fraction.
The constituents present were further separated by HPLC
using a LaChrom Elite HPLC system (VWR Hitachi) and a 3
µm pentafluorophenyl (PFP, 150 x 4.60 mm, Phenomenex)
column. Detection was performed by diode array detection
(DAD). The profile of gradient elution was: double-distilled
water (ddH2O) (A) and methanol (B); 0-15 min, from 50 to
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100% B; 15-25 min 100% B; 25-40 min from 100 to 50% B.
Separated constituents of repeatedly injections were collected,
pooled and dried under nitrogen for bioactivity testing.
NMR and HRFTMS
The NMR spectral data of the isolated bioactive compound
are identical to those reported in the Aldrich Library of 13C and
1H FT NMR Spectra (Pouchert, C. J., and J. Behnke, The
Aldrich Library of 13C and 1H FT-NMR Spectra, 75 and 300
MHz, Aldrich Chemical Company, Milwaukee, WI, 1993.) for 3-
(4-methoxyphenyl)-2-propenoic acid (E-form) also known as p-
coumaric acid methyl ester. The isolated compound was
elucidated by 1H (proton) and 2D HMBC (two-dimensional
Heteronuclear Multiple Bond Correlation) NMR spectroscopy
using a 400 MHz Jeol NMR system at SIPBS equipped with a
40TH5AT/FG probe. The compound’s molecular formula of
C10H10O3 was determined by direct injection on a HRFTMS
(high resolution Fourier transform mass spectrometer) using
the LTQ-Orbitrap. A commercially available reference standard
(Fluka No. 65420) was also used to confirm the structure and
chromatographic properties of the sample compound.
Zebrafish
For all experiments wild-type zebrafish embryos of the AB
and transgenic cmlc2:eGFP (cardiac myosin light chain
2:eGFP reporter) strains were used. Adult zebrafish were
reared under standard aquaculture conditions at 28.5°C on a
14/10 hour light/dark cycle. Embryos were collected after group
matings and kept in embryo medium (17 mM NaCl, 0.2 mM
KCl, 0.18 mM Ca(NO3)2, 0.12 mM MgSO4, 1.5 mM HEPES
buffer pH 7.1-7.3 and 0.6 µM methylene blue). Staging of
embryos was done according to Kimmel [21].
Ethics Statement
All animal procedures were performed in accordance with
Belgian and European Laws, guidelines and policies for animal
experimentation, housing and care (Belgian Royal Decree of 6
April 2010 and European Directive 2010/63/EU of 20 October
2010 on the protection of animals used for scientific purposes).
The Ethics Committee on Animal Experimentation of the
University of Leuven has approved this project with the number
P101/2010.
Compound Treatment of Embryos
Phenotypic screening was performed in 24-well plates, and
15 embryos were used per condition in a volume of 1 mL per
well. Each condition was tested in duplicate or triplicate. Test
solutions were prepared in embryo medium. The DMSO
concentration in each well never exceeded 2%. Continuous
treatment of embryos was done from the 2- to 4-cell stages up
to 48 hours post-fertilization (hpf). Pulse treatment with
compound for 1h was performed at tailbud stage (10 hpf) or 1
to 3-somites stages (10.5 - 11 hpf). Embryos were incubated at
28.5°C and dysmorphologies were scored at 24 hpf and 48 hpf.
Pictures were taken at 48 hpf, embryos were sedated with 1x
tricaine solution (80 µg/mL tricaine in 0.02% w/v sodium
phosphate), and methylcellulose was used to embed embryos.
Whole-Mount in situ Hybridizations (WISH)
Digoxigenin-UTP antisense RNA probes were synthesized
using the DIG Labeling Kit (Roche Diagnostics). For WISH
analysis, control and compound-treated embryos were fixed at
the appropriate developmental stages and were subjected to
an in situ protocol originally described by Thisse and Thisse
[22].
Microinjections of Morpholino Oligonucleotides
For jnk2 knockdown experiments, an antisense morpholino
oligomer (MO) designed to bind to an exon - intron junction of
the zebrafish jnk2 was synthesized by Gene Tools (Philomath,
Oregon). This MO has been described in a previous report [23].
A stock solution of 2 mM was microinjected into the yolk of 1-
to 2-cell stages AB embryos using an Eppendorf FemtoJet
microinjector. The injected dose was 8 ng per embryo.
Cells, culture conditions and treatments
Normal human keratinocytes were cultured in keratinocyte-
specific medium (Invitrogen). Cells were seeded 24 hours
before the experiment in 10 cm2 dishes, 106 cells per dish.
Cells were treated for 1 or 2 hours with vehicle (0.2% DMSO),
SP600125 (20 µM, 10 µM), or pCAME (56 µM, 7 µM, 3.5 µM).
Subsequently, anisomycin was added in a final concentration
of 10 µg/mL to cell medium. Anisomycin triggers stress-induced
apoptosis and thus activates Jnk signaling [24].
Immunoblot
Following 45 minutes of anisomycin treatment, cells were
washed twice with ice cold PBS buffer (Invitrogen) and lysates
were made with RIPA-buffer (Invitrogen). PhosStop (Roche)
phosphatase inhibitor cocktail and cOmplete (Roche) protease
inhibitor cocktail were added to lysis buffer. Protein
concentration was determined using BCA assay (Pierce BCA
Protein Assay Kit, Thermoscientific). Samples were prepared in
duplicate, loaded in a NuPage Novex 10% Bis-Tris gel
(Invitrogen) and subjected to SDS-PAGE. Proteins were
transferred to nitrocellulose membrane and probed with C-jun
and phosphorylated C-jun (p-C-jun, Ser63) monoclonal
antibodies (Cell signaling). Detection was performed using the
Odyssey infrared imaging system.
Imaging
Zebrafish embryos were photographed using a Leica MZ10F
stereomicroscope equipped with a DFC310 FX digital camera
run by Leica Application Suite software (version 3.6.0). Pictures
were processed using Microsoft Powerpoint and Office Picture
Manager.
Results and Discussion
Zebrafish-Based Screen of Plant Extracts to Identify
Bioactive Natural Products
A total of 3160 methanolic plant extracts from the Strathclyde
Natural Products Library (SNPL) were screened in zebrafish
embryos, with the aim of identifying bioactivities leading to
phenotypic defects reminiscent of BMP and Wnt mutants [4–7].
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Embryos at the 2- to 4-cell stages were subjected to
continuous incubation with 20 and 100 µg/mL of each plant
extract. Treated embryos were microscopically scored at 8, 24
and 48 hpf for morphological defects or death. 356 extracts
induced embryonic dysmorphologies. These extracts were
further assessed in a secondary screen for concentration-
dependency and reproducibility of the phenotype. Ten extracts
(hits) were selected for further analysis based on their ability to
induce BMP- and Wnt-like mutant phenotypes. Interestingly, an
extract obtained from Jasminum gilgianum (Oleaceae), a plant
native to Papua New Guinea, induced tail duplication in
zebrafish embryos.
Bioassay-Guided Isolation of para-Coumaric Acid
Methyl Ester (pCAME)
To isolate the active constituent responsible for this activity,
bioassay-guided fractionation of the J. gilgianum extract was
performed. The crude methanolic extract was first separated
using silica-based thin layer chromatography. Each band
detected was tested on zebrafish embryos, and the tail
duplication activity was identified in band 4 (see Figure 1A).
Preparative liquid chromatography was then performed to
obtain larger amounts of the primary constituents present in
this band, which were further separated by HPLC using DAD to
monitor the separation process. Each peak detected was
collected and tested for activity, thereby identifying the primary
peak (see Figure 1B) as inducing the tail duplication
phenotype. Identification and structural elucidation of the active
compound was performed using HPLC in combination with
HRFTMS (high resolution Fourier transform mass
spectrometry) and 2D NMR spectroscopy. The NMR spectral
data (see Figure 1D) of the isolated biologically active
compound from J. gilgianum was elucidated as (E)-methyl 3-(4-
hydroxyphenyl) acrylate also known as para-coumaric acid
methyl ester (pCAME) (Figure 1C). The compound’s molecular
formula of C10H9O3 for [M-H]- (calc. 177.0557; found 177.0556)
was determined by direct injection on an HRFTMS using an
LTQ-Orbitrap. A commercially available reference standard
was also used to confirm the structure and chromatographic
properties of the sample compound. Fortuitously, the
compound was commercially available and was purchased
from Frinton Laboratories for further experiments. NMR
analysis confirmed that the compound provided by the supplier
was identical to the active compound isolated from J.
gilgianum.
Phenotypic Characterization of pCAME-Treated
Embryos
The crude methanolic extract of Jasminum gilgianum
(Oleaceae) at a concentration of 100 µg/mL consistently
induced tail duplication in treated embryos (Figure 2A). A
concentration-response experiment was performed with pure
pCAME to analyze in more detail the phenotype/s induced by
this compound. Treatment of 2- to 4-cell stages embryos with
pCAME resulted in a dose-responsive shortening of the
anterior-posterior (AP) axis, (compare 28 µM pCAME (Figure
2C) with 14 µM pCAME-treated embryos (Figure 2D)).
Embryos treated with 14 µM pCAME displayed tail duplication,
although this phenotype had a variable penetrance, ranging
from 7 to 15%. Other dysmorphologies observed at 48 hpf
were the absence of pectoral fins, decrease in pigmentation,
body curvature, pericardial edema, cardia bifida (Figure 2E)
and synophthalmia (Figure 2H). Confirmation of the cardiac
defects was done using transgenic cmlc2:eGFP (cardiac
myosin light chain promoter driving eGFP) embryos treated
with 28 µM pCAME, in which 100% of treated embryos
displayed cardia bifida (Figure 2F). In an attempt to induce only
the (late) tail duplication phenotype without causing other
dysmorphologies due to perturbation of signaling pathways
required for early embryonic patterning, a pulse treatment was
performed at late tailbud to early somitogenesis stages.
Treatment with 140 µM pCAME for 1h at tailbud stage resulted
in embryos showing a milder decrease in general pigmentation
and tail duplication (Figure 2B) in up to 30% of the embryos.
Pulse treatment for 1h at 1- or 3-somite stages for 1h increased
the percentage of ectopic tail formation to 67 and 87%,
respectively.
Analysis of Tissue-Specific Marker Expression in
pCAME-Induced Ectopic Tails
Tail development in zebrafish starts from a pool of
undifferentiated cells in the tailbud. During tail protrusion,
several signaling pathways – including nodal, fibroblast growth
factor, BMP and Wnt pathways – play a concerted role in
regulating this process [25,26]. Pyati et al. studied the role of
BMP signaling in the ventral and posterior mesoderm during
mid- and late-gastrula stages [6], using a transgenic zebrafish
line expressing a dominant-negative BMP receptor-GFP fusion
protein inducible by heat shock [6]. This study showed that
from mid-gastrulation onwards, BMP signaling is important for
tail patterning and the inhibition of secondary tail formation. To
explore whether the same tissues in pCAME-induced ectopic
tails were affected as those previously reported after BMP-DN
overexpression, the following markers were used: myogenic
differentiation factor (myoD), sonic hedgehog (shh), no tail (ntl),
even-skipped1 (eve1), collagenase2a (col2a), crestin,
neurogenin1 (neurog1) and caudal type homeobox
transcription factor 4 (cdx4). Embryos were pulsed for 1h at
tailbud stage with 140 µM of pCAME and fixed at 30 hpf. The
secondary tails expressed both tailbud markers eve1 (Figure
3A) and ntl (Figure 3B). The ectopic tails contained muscle
tissue, as marked by myoD (Figure 3C) expression. Duplication
of the col2a (Figure 3D) expression domain proved the
presence hypochord cells while shh expression (Figure 3E)
revealed the presence of notochord cells. Of the neural tube
markers (neurog1 and cdx4), only cdx4 was expressed in the
ectopic tails (Figure 3F). Expression of the neural crest marker
crestin was not observed. Our marker analysis correlated well
with those reported by Pyati and colleagues [6]. In summary,
the ectopic tails were shown to possess tailbud cells, somites,
hypochord and notochord, but lacked neural tissue at 30 hpf.
pCAME Acts Synergistically with BMP Signaling
Inhibitors
Inhibition of BMP and/or non-canonical Wnt signaling can
lead to the formation of a secondary tail, according to the
Small-Molecule Inducer of Ectopic Tail Formation
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model of Yang et al [7]. In this model, both pathways have a
distinct function to ensure proper tail morphogenesis. The
anteriorward migration of the ventroposterior mesodermal
precursors in the tailbud is directed by BMP signaling
immediately prior to tail protrusion. These cells disrupt the
association of the caudal notochord cells with the yolk while
Figure 1.  Isolation of pCAME.  (A) Typical normal phase TLC separation of the crude methanolic extract of Jasminum gilgianum,
daylight view (left), plate sprayed with 1% vanillin/H2SO4 (right). Black star denotes band of interest. (B) Typical HPLC
chromatograms of preparative fraction 4 at 200 and 300 nm, black arrows denote signal due to pCAME. (C) Molecular structure and
molecular weight of pCAME. (D) NMR spectral data.
doi: 10.1371/journal.pone.0083293.g001
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Figure 2.  Phenotypic characterization of pCAME-treated embryos.  (A) Embryo treated with 100 μg/mL crude methanolic
extract of J. gilgianum. Black arrow denotes ectopic tail. Unless otherwise noted, all treatments were performed at 2- to 4-cell
stages. (B) Embryo treated with 140 μM pCAME pulsed 1h at tailbud stage, black arrow denotes ectopic tail; (C) pCAME-treated
embryo with 28 μM and with (D) 14 μM pCAME; (E) Embryo treated with 28 μM pCAME; black arrows denote 2 hearts; (F)
cmlc2:eGFP embryo treated with 28 μM pCAME; (H) Embryo treated with 28 μM pCAME; black double arrow indicates
synophthalmia; (G) and (I) Vehicle-treated control (1% DMSO), black double arrow denotes normal distance between eyes. All
embryos are at 48 hpf. The main phenotypic characteristics of pCAME-treated embryos are: tail duplication, AP-axis shortening,
absence of pectoral fins, decrease in pigmentation, body curvature, synophthalmia and cardia bifida.
doi: 10.1371/journal.pone.0083293.g002
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migrating. During this process, non-canonical Wnt signaling
increases intracellular adhesion in the caudal notochord cells
by influencing the localization of cadherin to the plasma
membrane, thereby promoting the association of caudal
notochord cells. Ectopic tail formation has been reported to
occur in BMP-deficient embryos. A defective migration of the
mesodermal progenitors can heavily disturb the caudal
notochord cells. Isolation of caudal notochord cells from the
rest of the pool during tail protrusion then leads to tail
bifurcation. This phenomenon has also been observed in
embryos defective in non-canonical Wnt signaling. Due to a
lack of sufficient cadherin at the plasma membrane, cohesion
is not strong enough to keep the caudal notochord cells
together. Again, caudal notochord cells become isolated and
thus, form an ectopic tail. The secondary tails are ventrally
positioned and contain muscle and notochord tissue. Yang et
al. demonstrated that by simultaneously inhibiting both BMP
and non-canonical Wnt signaling, the percentage of ectopic
tails increases [6,7]. During early gastrula stages, BMP is
crucial for dorsoventral patterning of the embryo. An inhibition
of BMP at early stages of development results in a
phenotypically dorsalized embryo [27]. This phenotype was
never observed in pCAME-treated embryos. Therefore, it is not
likely that pCAME interferes with early BMP signaling but
rather, based on previous reports and our own data, influences
non-canonical Wnt/PCP signaling.
Based on these findings, an experiment was carried out
using dorsomorphin, a small-molecule inhibitor of the BMP
pathway, and its more BMP receptor-selective structural analog
LDN-193189 [8,28]. We postulated that if pCAME acts as an
inhibitor of non-canonical Wnt signaling, then an increase in the
percentage of tail duplications should be seen when pulsed
together with BMP inhibitors. Embryos between tailbud and
early somitogenesis stages were pulsed for 1h with 70 µM
pCAME in the absence or presence of 5 µM or 10 µM
dorsomorphin/LDN-193189.
Table 1 represents the result of the 3 combined experiments.
Pulsing with subthreshold doses of either 70 µM pCAME, 5 or
10 µM dorsomorphin alone resulted in very few embryos
displaying ectopic tails (2.2% for 70 µM pCAME and 10 µM
dorsomorphin, and 0% for 5 µM dorsomorphin). However, the
pulse combination of 70 µM pCAME with 10 µM dorsomorphin
yielded 55.5% ectopic tails, while a pulse combination of 70 µM
pCAME with 5 µM dorsomorphin yielded 24.4% ectopic tails.
Figure 3.  Analysis of tissue-specific marker expression in pCAME-induced ectopic tails.  (A) eve1; (B) ntl; (C) myoD; (D)
col2a; (E) shh; and (F) cdx4 expression. All embryos were pulsed with 140 μM pCAME for 1h at tailbud stage and fixed at 30 hpf.
Lateral views.
doi: 10.1371/journal.pone.0083293.g003
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The results of the pulse combination experiment of 70 µM
pCAME and 10 µM dorsomorphin are displayed in Figure 4.
Thus a significant increase (p<0.001; Fisher’s exact test) in the
percentage of ectopic tails was observed when subthreshold
doses of pCAME and dorsomorphin were administered in
combination. Moreover, the ectopic tails were phenotypically
more pronounced. Pulsing with 50 µM dorsomorphin alone
yielded a maximum of 25.9% ectopic tails.
As more recent findings indicate that dorsomorphin may
have additional targets, we also analyzed a more selective
BMP inhibitor, LDN-193189 [28]. As shown in Table 2, pulsing
with 70 µM pCAME resulted in 6.7% ectopic tails. Pulsing with
5 or 10 µM LDN-193189 did not yield any tail duplications.
When we combined the conditions, an increase in ectopic tail
formation was observed, and the effect was larger than the
combined effects of each compound. The combinations with 70
µM pCAME and 10 µM LDN-193189 yielded 35.6% and the
combination with 5 µM LDN-193189 yielded 26.7% ectopic
tails. Similar to the results obtained after combined exposure to
pCAME and dorsomorphin, a significant increase (p<0.001;
Fisher’s exact test) in the percentage of ectopic tails was
observed when subthreshold doses of pCAME and
LDN-193189 were administered in combination. Pulsing with
80 µM, an 8-fold higher concentration of LDN-193189, yielded
a maximum of 23.3% ectopic tails.
In conclusion, the mechanism by which pCAME induces
ectopic tails appears to be synergistic with that of
dorsomorphin or LDN-193189. This further supported our
hypothesis that pCAME modulates non-canonical Wnt
signaling, one of the key signaling pathways important for
proper tail morphogenesis.
Table 1. Pulse experiment with pCAME and dorsomorphin.
Condition Total n Ectopic tails Synergy Yes/No Fisher’s Exact test P< 0.001
Control 45 0.0 % n/a  
pCAME 70 µM 45 2.2 % n/a  
Dorsomorphin 10 µM 45 2.2 % n/a  
Dorsomorphin 5 µM 45 0.0 % n/a  
pCAME 70 µM + Dorsomorphin 10 µM 45 55.5 % Yes ***
pCAME 70 µM + Dorsomorphin 5 µM 45 24.4 % Yes ***
Note: Embryos were pulsed for 1h at late gastrula/early somitogenesis (bud to 3-somite stages) and scored at 48 hpf; n/a: not applicable; Table represents data pooled from
three independent experiments using (each time) 15 embryos per condition. Fisher’s exact test: Pulse combinations vs. Control condition vs. pCAME condition vs.
Dorsomorphin conditions
doi: 10.1371/journal.pone.0083293.t001
Figure 4.  Synergy between pCAME and dorsomorphin.  (A) Wild type pulsed with 1% DMSO in Danieau’s solution; (B) 10 µM
dorsomorphin pulse; (C) 70 µM pCAME pulse; (D) and (E) Combination of 10 µM dorsomorphin and 70 µM pCAME pulse. Black
arrows denote ectopic tails. All AB embryos are at 48 hpf and pulsed for 1h at tailbud stage. A significant increase of the percentage
of ectopic tail formation was observed as well as a more pronounced phenotype.
doi: 10.1371/journal.pone.0083293.g004
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Convergence and Extension Defects Induced by
pCAME
Convergence-extension (CE) movements occur during
gastrulation, when cells migrate to and intercalate at the dorsal
midline and as such, extend the embryo along the anterior-
posterior (AP) axis. Both BMP signaling and non-canonical Wnt
are important for proper CE movements [29–31]. To visualize
CE defects in pCAME-treated embryos, WISH analyses were
performed with the following markers: floating head (flh), ntl,
paraxial protocadherin (papc), myoD and an in situ
hybridization probe cocktail of distal-less homeobox gene 3
(dlx3), shh, and hatching gland (hgg). Embryos were treated at
2- to 4-cells stages with 14 and 28 µM pCAME and fixed at 1-
or 5-somites stages. Compared to wild-type embryos, the
compound-treated embryos displayed a wider and shorter
notochord, as visualized by flh and ntl expression (Figure 5A,
B, C, D and A’, B’, C’, D’). The edges of the para-axial
mesoderm, as marked by papc, are farther apart, suggesting
CE defects (Figure 5E, F and E’, F’). The somites (myoD
expression pattern) do not converge all the way to the midline
and do not extend anterior-posteriorly as in controls (Figure
5G, H and G’, H’). Furthermore, the expression domain of dlx3
in the neural plate was expanded both in 14- and 28 µM-
treated embryos (data not shown). Overall, the different
markers tested provided supporting evidence that CE
movements in pCAME- treated embryos were impaired. Thus,
pCAME was most likely interfering with one of the pathways
that ensure proper CE movements in the gastrulating zebrafish
embryo.
Investigation of C-jun N-terminal Kinase (Jnk) as a
Possible Target of pCAME within Wnt/PCP Signaling
Given that structurally-related compounds of pCAME were
reported to inhibit both MAP kinases and tyrosine kinases
[32,33], we looked for possible kinase targets present in the
Wnt/PCP pathway. C-jun N-terminal kinase (Jnk) belongs to
the family of MAPKs, and is downstream of the receptor
complex of the Wnt/PCP pathway, becoming activated by Rac
GTPase [34]. The Jnk family in mammals is encoded by three
related genes: jnk1, jnk2 and jnk3. In zebrafish, 4 jnk genes
have been identified that give rise to the following proteins:
Jnk1a-1, Jnk1a-2, Jnk2 and Jnk3. During gastrulation, only
transcripts of jnk1a-1, jnk1a2 and jnk2 are present. Morpholino
knockdown of jnk1a-1 and jnk1a-2 had no phenotypic effect on
zebrafish embryos. Knockdown of jnk2, on the other hand,
induced severe CE defects and was found to be important for
normal CE movements during zebrafish gastrulation [23].
In our hands, jnk2 morpholino knockdown resulted in 38% of
injected embryos displaying body curvature (Figure 6A), and
9% of the embryos displaying a complete lack of a tail (Figure
6B). These embryos are reminiscent of 28 µM pCAME-treated
embryos (Figure 2C). 53% of injected embryos were normal
(Figure 6C), and no tail duplications were observed in these
knockdown fish. Notably, however, tail duplication is only
induced in a large percentage of embryos after pulse treatment
with pCAME at late tailbud to early somitogenesis stages.
jnk2 knockdown has previously been shown to impair
Wnt/PCP signaling and therefore to cause CE defects in
zebrafish embryos [23]. Our results also show the notochord of
jnk2 morpholino-injected fish to be broader and shorter, as
visualized by WISH with flh and ntl (Figure 6E-E’-F-F’). The
myoD expression pattern indicated that the convergence of the
somites was impaired (Figure 6G-G’), while the papc
expression pattern indicated a failure of the para-axial
mesoderm to extend (Figure 6H-H’). In addition, the neural
plate was broader than normal, as indicated by dlx3 expression
(data not shown). Together with the previously reported
findings [23], these data indicate that knockdown of jnk2
causes CE defects.
Since it was not possible to test for induction of ectopic tails
in jnk2 MO-injected embryos, we used a known small-molecule
inhibitor of Jnk, SP600125, to perform pulsed Jnk2 inhibition
experiments. SP600125 was discovered by Bennett et al. as a
reversible ATP-competitive inhibitor of Jnk [35–37]. Embryos at
tailbud stage were pulsed for 1 hour with different
concentrations of SP600125 (200, 150, 100, 50 and 1 µM).
Embryos pulsed with 1 and 50 µM appeared normal. At higher
concentrations, embryos displayed ectopic tail formation: 30%
at 150 and 200 µM; 16.7 % at 100 µM. A representative picture
of an embryo pulsed with 150 µM SP600125 is displayed in
Figure 6D.
WISH analysis was performed to determine whether the
expression pattern of tissue markers in SP600125 ectopic tails
resembled that of pCAME-treated embryos. The same markers
were used as previously: myoD, shh, ntl, eve1, col2a, crestin,
Table 2. Pulse experiment with pCAME and LDN-193189.
Condition Total n Ectopic tails Synergy Yes/No Fisher’s Exact test P< 0.001
Control 90 0.0% n/a  
pCAME 70 µM 90 6.7% n/a  
LDN-193189 10 µM 90 0% n/a  
LDN-193189 5 µM 90 0% n/a  
pCAME 70 µM + LDN-193189 10 µM 90 35,6% Yes ***
pCAME 70 µM + LDN-193189 5 µM 90 26.7% Yes ***
Note: Embryos were pulsed for 1h at late gastrula/early somitogenesis (bud to 3-somite stages) and scored at 48 hpf; n/a: not applicable; Table represents data pooled from
three independent experiments using (each time) 30 embryos per condition.
Fisher’s exact test: Pulse combinations vs. Control condition vs. pCAME condition vs. LDN-193189 conditions
doi: 10.1371/journal.pone.0083293.t002
Small-Molecule Inducer of Ectopic Tail Formation
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e83293
neurog1 and cdx4. Embryos were pulsed for 1h at tailbud stage
with 150 µM of SP600125 and fixed at 30 hpf. The ectopic tails
possessed tailbud cells (Figure 7A-B), somites (Figure 7C),
hypochord (Figure 7D) and notochord (Figure 7E) tissue. From
the neural tube markers, only cdx4 was present in the ectopic
tails (Figure 7F). No duplication of the expression domain of
neurog1 and crestin was seen. In conclusion, the tissue-marker
expression patterns observed in the ectopic tails induced by
pulsing with 150 µM SP600125 were identical to those of
pCAME-treated embryos.
Based on this data, an in vitro experiment was performed to
check the inhibitory capacity of pCAME on Jnk kinase activity.
Normal human keratinocytes (HK) were treated for 1h or 2h
with vehicle, SP600125 or pCAME, subsequently activated with
anisomycin (10 µg/mL) and lysed. Upon activation by
anisomycin, Jnk phosphorylates its downstream targets,
including C-jun. C-jun is a component of the activator protein-1
(AP1) transcription factor [38,39]. After blotting on nitrocellulose
membrane, levels of C-jun protein and phosphorylated C-jun
(p-C-jun) protein were detected. In the event that Jnk would be
inhibited during cell activation, levels of p-C-jun would
decrease. Figure 8 displays a representative immunoblot for C-
jun and p-C-jun protein. SP600125 displayed an inhibitory
effect on both total C-jun and p-C-jun levels in activated HK
cells after 1 hour of treatment. In contrast, pCAME did not
decrease levels of p-C-jun after 1 hour of treatment. Increasing
the treatment time to 2 hours still did not affect p-C-jun levels.
Figure 5.  pCAME induces convergence and extension defects.  (A) and (B) flh expression; (C) and (D) ntl; (E) and (F) papc;
(G) and (H) myoD. All embryos were treated at 2-4 cell stages with 14 or 28 μM pCAME and fixed at 1 somite stage. Dorsal view.
Expression domains of compound-treated fish are altered as would be predicted for CE defects. Embryos have a broader and
shorter notochord and impaired convergence and extension of the para-axial mesoderm and the somites.
doi: 10.1371/journal.pone.0083293.g005
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To summarize, we observed that morpholino knockdown and
pharmacological inhibition of Jnk by SP600125, phenocopies
pCAME-treated embryos. However, the immunoblotting
experiments revealed that pCAME has no effect on C-Jun
phosphorylation. Based on this data, pCAME does not appear
to inhibit Jnk – at least not directly. Although SP600125 is
generally used as specific Jnk inhibitor [35–37], the compound
is able to inhibit more kinases then only Jnk isoforms.
According to studies of Bain et al., several other protein
kinases included in their test panel were inhibited with similar
or greater potency by SP600125 [40]. Thus, it is possible that
the ectopic tail phenotype we observe may be due to an
inhibition of another kinase different from Jnk, kinases farther
downstream of Jnk signaling, or even multiple kinases.
Evidence for a multi-target action of pCAME is based on
previous reports describing it as an inhibitor of tyrosinase, an
enzyme that is responsible for the production of melanin
[41–43]. We performed a comparative test in zebrafish using
phenyl thiouracil (PTU), another known tyrosinase inhibitor.
Aside from the lack of pigmentation, no pCAME-like
dysmorphologies or ectopic tail formation was seen in embryos
pulsed with PTU. Therefore we believe that the decrease in
pigmentation seen in pCAME-treated embryos is solely due to
tyrosinase inhibition, and that this activity is separate from the
other phenotypes observed. Moreover, the possibility that
pCAME could modulate other pathways essential for zebrafish
tail formation such as those of Nodal and Fgf are unlikely as
left-right asymmetry defects were never observed in pCAME-
Figure 6.  jnk2 morpholino knockdown induces convergence extension defects.  (A) and (B) 2 mM jnk2 MO-injected fish A: 38
% B: 9 %; (C) Wild type; (D) 150 μM SP600125 pulsed for 1 h at tailbud stage. All embryos are at 48 hpf. Black arrow denotes
duplicated tail. (E-H) Control MO injected fish; (E’-H’) jnk2 MO injected fish; (E) flh; (F) ntl; (G) myoD; (H) papc.
doi: 10.1371/journal.pone.0083293.g006
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treated embryos and the midbrain-hindbrain boundary
remained fully intact (data not shown)[44,45].
Conclusions
This study indicates the usefulness of zebrafish as an in vivo
bioassay for the identification of novel natural products that
Figure 7.  Tissue marker analysis in SP600125-induced ectopic tails.  (A) eve1; (B) ntl; (C) myoD; (D) col2a; (E) shh; and (F)
cdx4 expression. All embryos were pulsed with 140 μM pCAME for 1h at tailbud stage and fixed at 30 hpf. Lateral views.
doi: 10.1371/journal.pone.0083293.g007
Figure 8.  Immunoblot of C-jun and phospho-C-jun.  Representative immunoblot of C-jun and phospho-C-jun protein for
investigating the inhibitory capacity of pCAME on Jnk. HK cells were treated for 1 or 2 hours with vehicle, SP600125 or pCAME,
subsequently activated with anisomycin (10 µg/mL) and lysed.
doi: 10.1371/journal.pone.0083293.g008
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inhibit developmental pathways relevant for human disease. In
this work, para-coumaric acid methyl ester was isolated from
the crude methanolic extract of Jasminum gilgianum, a plant
native to Papua New Guinea, on the basis of this molecule’s
ability to induce ectopic tail formation in zebrafish embryos.
These secondary tails were positioned ventrally and have
tailbud cells, somites, hypochord and notochord tissue present.
No evidence for presence of neural tissue was found. This
phenotype is highly reminiscent of the one obtained upon
overexpression of a dominant-negative BMP receptor in post-
gastrula zebrafish embryos [6] and following inhibition of BMP
and/or non-canonical Wnt signaling, according to the model of
Yang et al. [7].
According to this model [7], two pathways are involved in
ectopic tail formation: BMP and non-canonical Wnt signaling.
Both pathways play a role in preventing the caudal notochord
cells of the tail bud from sloughing off and forming a secondary
tail as tail protrusion proceeds. Our experimental data suggests
that pCAME interferes likely with non-canonical Wnt signaling.
Furthermore, we observed that SP600125 is able to induce
identical ectopic tails. However, the immunoblotting
experiments to assess levels of C-Jun and p-C-Jun excluded
Jnk as a direct target of pCAME. Therefore, other kinases
targeted by SP600125 could also be possible targets of
pCAME. Further research will be required to identify this
compound’s precise mechanism of action.
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